REGENXBIO Inc. (NASDAQ:RGNX) Receives $35.45 Average PT from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has earned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $35.45.

A number of research analysts have issued reports on RGNX shares. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a report on Wednesday, September 4th. Barclays dropped their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Finally, Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Tuesday.

REGENXBIO Trading Down 2.4 %

RGNX opened at $9.35 on Wednesday. REGENXBIO has a 1-year low of $9.11 and a 1-year high of $28.80. The stock has a market capitalization of $460.54 million, a PE ratio of -1.59 and a beta of 1.21. The firm has a 50-day moving average price of $11.10 and a two-hundred day moving average price of $13.05.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The business had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $22.97 million. During the same period in the prior year, the firm earned ($1.66) earnings per share. REGENXBIO’s revenue was up 11.6% compared to the same quarter last year. On average, research analysts predict that REGENXBIO will post -4.66 EPS for the current year.

Insider Activity at REGENXBIO

In other REGENXBIO news, Director Argeris N. Karabelas sold 11,000 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the transaction, the director now owns 11,286 shares of the company’s stock, valued at $169,741.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other REGENXBIO news, Director Argeris N. Karabelas sold 11,000 shares of REGENXBIO stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $165,440.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at approximately $169,741.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,848 shares of company stock valued at $665,197. 13.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its stake in shares of REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 746 shares in the last quarter. nVerses Capital LLC raised its position in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in REGENXBIO in the first quarter valued at $56,000. Headlands Technologies LLC grew its position in shares of REGENXBIO by 276.8% in the 1st quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 2,812 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.